Please provide your email address to receive an email when new articles are posted on . Patients in a Veterans Affairs study who took two common diuretics showed no difference in outcomes for ...

Please provide your email address to receive an email when new articles are posted on . Longer use of hydrochlorothiazide was linked to an increased risk for keratinocyte carcinoma and melanoma.

Patients with severe hypertension are at high risk for cardiovascular events. The authors hypothesized that initial treatment with a combination angiotensin receptor blocker/diuretic agent would be ...

Study findings challenge standard use of thiazide and thiazide-like diuretic agents to reduce the risk of kidney stone recurrence. The thiazide diuretic hydrochlorothiazide does not prevent kidney ...

Thiazide diuretics remain as one of the drugs most commonly used to treat systemic arterial hypertension. In particular, hydrochlorothiazide (HCTZ) is one of the first-line antihypertensive therapy ...

Compared with HCTZ, chlorthalidone better decreases risk for MACEs and noncancer death in patient with hypertension and history of MI or stroke. Researchers sought to compare CTD vs HCTZ and ...

CHICAGO, IL—Chlorthalidone does not reduce major adverse cardiovascular events compared hydrochlorothiazide in older, predominantly male military veterans with hypertension, according to the ...

The first fixed-dose combination involving Novartis’first-in-class oral renin inhibitor, Tekturna with hydrochlorothiazide (HCT)was approved in the USin January 2008. A single-tablet combination with ...

Tekturna HCT approved for hypertension The FDA has approved an expanded indication for Tekturna HCT (aliskiren/hydrochlorothiazide tablets, from Novartis) to include initial therapy for patients with ...

To date, there have been no reports of any adverse events related to this recall. Accord Healthcare announced a voluntary recall of 1 lot of Hydrochlorothiazide tablets USP, 12.5mg, after a product ...

The primary end point was the proportion of patients achieving goal mean trough SiDBP (<90 mm Hg) after 4 weeks of therapy with either losartan 50 mg/HCTZ 12.5 mg or a losartan monotherapy regimen ...